Protagonist Therapeutics Shares Bounce Back From 52-Week Low Monday
Protagonist Therapeutics Shares Bounce Back From 52-Week Low Monday
By Stephen Nakrosis
作者：斯蒂芬·納克西
Shares of Protagonist Therapeutics, Inc. are trading higher on the Nasdaq Tuesday, a day after the company's shares touched a 52-week low following news the Food and Drug Administration placed studies of the company's lead asset rusfertide on a clinical hold.
主角治療公司的股票週二在納斯達克交易走高，此前一天，該公司股價觸及52周低點，原因是有消息稱，美國食品和藥物管理局(Food and Drug Administration，FDA)暫停了對該公司主要資產黃麴黴毒素的研究。
At 12:34 p.m. EDT, the company's shares were trading 17.45% higher at $15.21 a share. Volume at the time topped 5.3 million shares, above the stock's 65-day average volume of 732,796.
中午12點34分美國東部夏令時，該公司股價上漲17.45%，至每股15.21美元。當時成交量超過530萬股，高於該股65日平均成交量732,796股。
On Monday, the stock touched a 52-week low of $12.80 a share and finished the day with a 26.13% loss, closing at $12.95.
週一，該股觸及每股12.80美元的52周低點，收盤時下跌26.13%，收於12.95美元。
On Friday, the company said it received a verbal communication from the FDA that clinical studies for rusfertide, "an investigational product candidate currently in development," were placed on a clinical hold. The company said it notified the FDA that benign and malignant subcutaneous skin tumors were observed in a 26-week rasH2 transgenic mouse model study.
週五，該公司表示，它收到了FDA的口頭通知，即“目前正在開發的一種試驗性候選產品”--魯西肽的臨牀研究已被擱置。該公司表示，它通知了FDA，在一項為期26周的rasH2轉基因小鼠模型研究中觀察到了良性和惡性的皮下皮膚腫瘤。
Protagonist said it is "working with the FDA and will be prepared to make all appropriate updates to clinical study documents and determine the next steps in consultation with the FDA."
Proagonist説，它正在與FDA合作，並將準備對臨牀研究文件進行所有適當的更新，並與FDA協商確定下一步行動。
The company's shares saw a 52-week high of $50.54 each on Sept. 7.
9月1日，該公司股價創下52周新高，達到每股50.54美元。7.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
寫信給斯蒂芬·納克希爾斯，電子郵件：stehen.naksim@wsj.com
譯文內容由第三人軟體翻譯。